Skip to main content

Paroxysmal Supraventricular Tachycardia (PSVT)

Striving towards a Heart-Healthy Future Through Innovative Therapies

Ever Experienced a PSVT Episode?

The RAPID Clinical Study is Now Enrolling People Suffering from Sudden, Rapid Heartbeats.

Paroxysmal Supraventricular Tachycardia (PSVT) is an arrhythmia (heart rhythm disorder). PSVT results in episodes of sudden and rapid heart rates that are usually at a rate greater than 100 beats per minute. A normal heart rate is about 60 beats per minute. 

The RAPID Study is a clinical research study for adults with Paroxysmal Supraventricular Tachycardia. Revival Research Institute is currently enrolling people with this condition.  

You may qualify for the RAPID study if you:

  • Are 18 years or older
  • Have been diagnosed with PSVT heart
  • Have a history of Paroxysmal Supraventricular Tachycardia episodes lasting for 20 minutes or more

The purpose of the RAPID study is to determine whether the study drug, a portable nasal spray, is effective in stopping an episode of Paroxysmal Supraventricular Tachycardia. Thousands of people suffer silently through PSVT. Clinical trials may provide options to people suffering from this condition.

*Participation in the RAPID Clinical Trial is free of cost to both you and your insurance. Please fill out the form to determine if you qualify for the study. Someone from our research team will give you a call and they might ask you questions about your medical history as well as information about any medications you are currently using.

**If you qualify and decide to participate, you will receive study-related care from experienced healthcare professionals including Cardiologists and nurses.

paroxysmal supraventricular tachycardia study

About the RAPID Study

The study takes place in approximately 175 study centers in the United States, Canada, and Europe. As many as 500 (or more) men and women, ages 18 or older, will be enrolled in this study.  

Revival Research Institute is conducting the RAPID study to determine if the study drug, a portable self-administered nasal spray, is an effective treatment for stopping an episode of Paroxysmal Supraventricular Tachycardia. Study participants may qualify to receive the new, experimental treatment available through our no-cost clinical study. The experimental medication is easy-to-use and may be able to help treat PSVT heart episodes in an in-home setting. 

Participants may pre-qualify for the RAPID study, if they are 18 years or older, have been diagnosed with Paroxysmal Supraventricular Tachycardia, and have PSVT episodes that last for 20 minutes or longer. All participants will receive study-related care, free-of-cost. And will receive complete study care from experienced healthcare professionals who have experience in clinical research and hospital settings.

*If you suffer from PSVT episodes and would like to participate in our Cardiology Clinical Trials, please fill the form above. Someone from our research team will give you a call to see if you qualify for the study.

*Participation in clinical research studies is completely voluntary. All participants have the right to withdraw from any of the studies. Withdrawal would mean that you might not receive the stipends that participants receive for each of the visits completed.

Get Started: What to Expect?

Pre-qualified patients will be subjected to a screening procedure that may involve a phone call and a visit to one of our 50-mile radius Revival locations. If you meet the criteria and want to participate in the research study, you will be monitored closely and taken care of, by medical staff with experience in Clinical Studies. 

If you qualify for the RAPID study and decide to participate, you will have a 2 in 3 chance of being randomly assigned to receive the study treatment and 1 in a 3 chance of being randomly assigned to receive placebo. The placebo is a medicine or procedure prescribed for the psychological benefit to the patient rather than for any physiological effect. In other words, the placebo is a medication, without any active ingredients. Neither you nor the study team will know which group you have been assigned.

*Participation in the RAPID research study is free-of-cost to you and no insurance is required.

Condition

Paroxysmal Supraventricular Tachycardia (PSVT)

Length of Study Treatment

Approx. 6 months

Number of Study Visits

7 visits

About Paroxysmal Supraventricular Tachycardia (PSVT)

A normal heart rate is between 60 to 100 beats per minute (bpm), but an episode of Paroxysmal Supraventricular Tachycardia may increase it over 250 bpm. While having a PSVT heart is not life-threatening, symptoms may be alarming because of the unexpectedness of episodes combined with the rapid heart rate. Some people experience significant anxiety and fear of the next episode. The episodes themselves may be debilitating and exhausting, leading some to avoid certain activities or withdraw from their normal routines.

Symptoms of Paroxysmal Supraventricular Tachycardia

Everyone’s PSVT episode experience is unique, however, some of the most common symptoms include: 

  • Rapid pulse 
  • Chest pressure or pain 
  • Shortness of breath 
  • Anxiety
  • Lightheadedness or dizziness 
  • Fainting 
  • Sudden onset of fatigue

Frequently Asked Questions

What is a study drug?

A study drug or an investigational drug is an experimental drug. It means that it is still being tested and has not been approved in the world by any drug regulatory body for use. It can only be used in research studies like this one.

What is Paroxysmal Supraventricular Tachycardia?

PSVT is a heart condition in which the rhythm of the heart is abnormal. It develops due to issues in the electrical conductivity of the heart’s fibers. This results in rapid and sudden heartbeats that can leave one in discomfort. It is generally not life-threatening, however, it can cause heart pain (angina) or congestive heart failure.

Which is the most common abnormal heart rhythm in cases of sudden cardiac arrest in adults?

Arrhythmias like Paroxysmal Supraventricular Tachycardia and Ventricular Fibrillation can cause sudden cases of cardiac arrest. This typically occurs due to improper conduction of electrical signals in the heart. This can lead to abnormal heartbeats.

What if I decide to discontinue my participation in the RAPID Study?

Your participation in the RAPID Study is completely voluntary. You may decide to discontinue at any time and for any reason.

How long will the study last?

If you qualify and decide to participate in the RAPID Study, your participation will last until you have treated two PSVT episodes with the study drug or until the study ends, which will be approximately six months after 180 other patients have had a PSVT episode and taken the study drug.

logo-normal

We are dedicated to advancing medicine & redefining patient care, one clinical trial at a time — with compassion. We are a network of clinical trial sites based in Michigan, & Texas.

Quick Links

Quick Links

Contact Info

  • 28270 Franklin Road, Suite F
    Southfield, MI 48034
  • 248-721-9539
Close Menu